Objectives: The 21-gene Breast Cancer Test (Oncotype DX®) is a validated diagnostic test that predicts the likelihood of adjuvant chemotherapy benefit and breast cancer recurrence in selected patients with early-stage breast cancer. A previous cost-effectiveness analysis of this test versus standard French clinical practice was published in 2012. Since then, docetaxel is no longer reimbursed on top of the diagnosis related groups (DRGs). The objective of this study was to update the costeffectiveness analysis considering this change. MethOds: The cost-effectiveness analysis was conducted using a Markov model including three health states (survival without recurrence, metastatic recurrence at ten years and death). Previous cost analyses were updated in order to assess the current overall costs of chemotherapy in public and private hospitals, considering that doxetaxel is not anymore reimbursed on top of DRGs. Unit costs were updated to 2015 values and other model parameters were collected from published literature. This study was conducted from the societal perspective. Deterministic sensitivity analyses were conducted to identify key drivers of the results. Results: Chemotherapy costs (standard deviation) per patient were estimated at € 10,917 from the societal perspectivein public hospitals. The incremental number of life years gained over 30 years was 0.15; the incremental number of QALYs gained was 0.14. Using the test was found to be costeffective versus usual care with a cost per QALY ratio of € 3,453 in public hospitals (€ 4,147 in private) from public perspective and a dominant strategy with a net costsaving per patient of € 658 in public hospitals (€ 449 in private) when considering costs of absenteeism. cOnclusiOns: While the cost of chemotherapy decreased considerably after the inclusion of docetaxel in the DRGs, the use of the 21-gene test is still cost-effective compared to usual care in French public and private hospitals from a societal perspective.
Objectives: To conduct a cost-effectiveness analysis of primary and secondary prophylaxis (PP & SP) with long acting granulocyte colony-stimulating factors (G-CSFs), such as pegfilgrastim, lipegfilgrastim, and short acting G-CSFs (i.e. filgrastim or lenograstim used in a 6-day regimen) for chemotherapy-induced febrile neutropenia (FN) in patients with non-Hodgkin's Lymphoma (NHL) in Greece. MethOds: An economic model that comprises a decision tree and a Markov chain, consisting of two phases, was locally adapted to reflect outcomes from payer perspective. The analysis was conducted for a lifetime horizon, across two different chemotherapy schemes (CHOP and CHOP-R). Clinical inputs included baseline FN risks, efficacy of G-CSFs, mortality, effects of FN on relative dose intensity, as well as direct medical costs for drug acquisition and administration and FN management. Input values were extracted from published studies while those for costs (2015 EUD) were obtained from local resources. Model outcomes were FN events avoided, and treatment strategies were compared by calculating incremental costeffectiveness ratios (ICERs) per FN event avoided. Results: PP with pegfilgrastim provided greater health benefits in terms of FN events (calculated by combining FN risk with the efficacy of G-CSFs: 0.164) followed by PP with lipegfilgrastim (0.243) and SP with pegfilgrastim (0.522). PP with pegfilgrastim was cost-effective versus SP with pegfilgrastim across all chemotherapy schemes (ICERs of € 7,490 for CHOP and € 7,781 for CHOP-R). SP with pegfilgrastim was cost-effective compared to SP with filgrastim (ICERs of € 1,657 for CHOP and € 1,836 for CHOP-R). SP with filgrastim was cost-effective compared to no prophylaxis (ICERs of € 1,404 for CHOP and € 1,585 for CHOP-R). The rest of the alternatives were dominated by a less expensive and more effective strategy. cOnclusiOns: Our analysis finds PP with pegfilgrastim to be a cost-effective option for chemotherapy-induced FN in NHL patients in Greece.
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Cost-EffECtivENEss iN thE sECoNd-liNE trEAtmENt of NoN-smAll CEll luNG CANCEr (NsClC) iN thE us
Graham C 1 , Knox H 1 , Hess LM 2 , Jen M 2 , Cuyun Carter G 2 , Chandrawansa K 2 , Boye M 2 1 RTI Health Solutions, Research Triangle Park, NC, USA, 2 Eli Lilly, Indianapolis, IN, USA Objectives: The objective of this study was to develop a cost-effectiveness model from a third-party payer perspective to evaluate second-line treatment strategies for NSCLC in the US and to investigate the value of ramucirumab+docetaxel (RAM+DOC) across histological subtypes. MethOds: Model comparators include the most commonly used second-line treatment regimens for NSCLC for which clinical trial data were available in the squamous, nonsquamous, and overall population. We used a lifetime horizon, 3% cost discounting rate, and semi-Markov structure to account for time-dependent variation in probabilities of progression-free and overall survival. The structure of the model incorporated 21-day cycles and four health states including second-line treatment, third-line treatment, best supportive (palliative) care, and death. Clinical trial data were supplemented by other published data, when necessary. Probabilistic and one-way sensitivity analyses were conducted to test the robustness of findings. Results: Based on the results of this cost-effectiveness analysis, RAM+DOC in the second-line treatment of patients may be considered a cost-effective option in the nonsquamous populations given an oncology willingness-to-pay threshold of $200,000 per life-year gained (ICER= $192,833 versus docetaxel alone). For the overall NSCLC population, comparators were limited and the incremental cost effectiveness ratio was slightly higher (ICER= $222,224 versus docetaxel). There were very limited data to evaluate the squamous population, and the ICER for RAM+DOC was high. The lack of complete data in the histological subgroups was a limitation; analyses were only possible for a subset of the comparators of interest. cOnclusiOns: The treatment patterns and cost data used to assumed to be a 50 year-old woman with HER2-positive metastatic breast cancer. Transition probability of each state in the model was estimated on the basis of the CLEOPATRA. As utility scores of Japanese metastatic breast cancer patients were not available, data from the NICE STA submission report were used. Costs were estimated on the basis of Japanese medical fee. Since our analysis was from the perspective of healthcare payer, only direct medical costs were included. Outcomes were measured in quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) was calculated. Two percent annual discount rate was used both for costs and outcome. The model used a time horizon of 25 years. Results: Additional pertuzumab in combination with trastuzumab and docetaxel can gain more QALY (on average 0.85 QALY) than trastuzumab and docetaxel therapy. ICER of pertuzumab compared with control estimated to be about JPY 17 million per QALY (around £ 90,000, £ 1 = JPY 190). cOnclusiOns: Pertuzumab in combination with trastuzumab and docetaxel is not cost-effective in our analysis, when £ 50,000 or less is judged to be cost-effective as ICER.
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Cost-EffECtivENEss of NilotiNib iN PAtiENts With ChroNiC myEloid lEukAEmiA EliGiblE to stArt thE trEAtmENt-frEE rEmissioN PhAsE iN itAly
Aiello A 1 , Daniel F 1 , D'Ausilio A 1 , Snedecor SJ 2 , Toumi M 3 1 Creativ Ceutical, Milano, Italy, 2 Pharmerit International, Bethesda, MD, USA, 3 Aix-Marseille
University, Marseille, France
Objectives: To assess the cost-utility of first-line nilotinib vs imatinib in patients with chronic myeloid leukaemia (CML) eligible to start the treatment-free remission (TFR) phase in the Italian healthcare setting (NHS). MethOds: A previous cost-utility model, simulating a cohort of 20,000 patients individually followed, was adapted to the Italian NHS. CML patients could start treatment with nilotinib or imatinib while for both arms a second-line with nilotinb is expected according to the Italian clinical practice. Patients remaining on first-line at thirty-six months and with a BCR-ABL score less than MR4.5 are considered long-term responders and may enter the treatment free remission (TFR) phase. Model outcomes are expressed in Quality-Adjusted-Life-Years (QALYs) and life-years-gained (LYG). Clinical data were derived from ENEST-nd trial. A panel of experts in CML treatment provided input on healthcare resource consumption: routine visits, laboratory/instrumental tests, adverse events management and drug consumption. Costs -Euros (€ ) 2015 -were quantified using Hospital National Tariffs and ex-factory drug prices. The model assumes that generic imatinib and nilotib become available as of January 2017 and July 2023,respectively, and therefore a 74% price discount for both drugs was included. Costs and outcomes were discounted at 3% according to Italian Guidelines for Economic Evaluations. Incremental cost-effectiveness ratios (ICERs) were calculated to estimate the incremental cost of a TFR patient with nilotinib. Results: An incremental number of 3,773 patients are eligible to TFR with nilotinib vs imatinib with € 33,748 total costs/patient. An improvement of +1.06 QALYs and +1.49 LYG is also observed in the nilotinib arm. The ICERs for nilotinib vs imatinib are € 39,935/ QALY and € 31,969/LYG. cOnclusiOns: The model shows that a greater number of patients enter TFR with nilotinib with acceptable ICERs vs imatinib.
PCN154 EstimAtiNG thE Cost-EffECtivENEss ProfilE of A vACCiNAtioN ProGrAmmE With A NiNE-vAlENt hPv vACCiNE iN itAly
Mennini FS 1 , Bianic F 2 , Baio G 3 , Largeron N 4 , Plazzotta G 5 , Rinaldi A 6 , De Waure C 7 , Bonanni P 8 1 Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome, Rome, Italy, 2 Mapi, Nanterre, France, 3 University College London, London, UK, 4 SPMSD, Lyon, France, 5 Mapi, Uxbridge, UK, 6 SPMSD, Roma, Italy, 7 Catholic University of Rome, Roma, Italy, 8 Universita' degli Studi di Firenze, Firenze, Italy Objectives: A new human papillomavirus (HPV) vaccine protects against the 9 HPV types responsible for 90% of HPV-related cancers (cervix, anus, vulva, vagina) . It includes the 4 types contained in the quadrivalent (HPV 6, 11, 16, 18) and 5 additional high-risk HPV types (HPV 31, 33, 45, 52, 58) . The analysis aimed at estimating the incremental public health impact and cost-effectiveness of 2 different interventions in Italy: 1) girl vaccination with a ninevalent HPV vaccine compared to a quadrivalent vaccine; 2) universal (girls and boys) vaccination programme with a ninevalent HPV vaccine compared to a quadrivalent vaccine. MethOds: A dynamic transmission model including a wide range of health and cost outcomes related to cervical, anal, vulvar, vaginal diseases and genital warts was calibrated to Italian epidemiological data. The clinical impact due to the 5 new types was included for cervical diseases only, producing conservative outcomes. In the base case, a two-dose schedule, lifelong vaccine type-specific protection and a vaccination coverage rate of 71% for the 12-year old cohorts were assumed. A threshold of 30,000€ /QALY-gained was considered. Different prices assumptions were used for the ninevalent vaccine (from 0% to 40% higher than that of the quadrivalent HPV vaccine). Deterministic sensitivity analyses on key parameters (such as duration of protection, discount rate) were conducted. Results: Over 100 years, between 21,000 to 22,000 cervical cancers and between 272,600 and 288,790 pre-cancerous cervical lesions could be avoided with the implementation of a ninevalent vaccine. The cost-effectiveness ratio of the ninevalent vaccine is estimated to remain well below the threshold with all the different price assumptions considered. cOnclusiOns: Both scenarios with a ninevalent vaccine in Italy are estimated to be from cost saving to highly costeffective across a range of sensitivity analyses and are expected to further reduce the public health burden of HPV-related cancers and diseases. 
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